Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Azer-cel + Cyclophosphamide + Fludarabine + Ibrutinib + Interleukin-12 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Azer-cel | azercabtagene zapreleucel | CD19 Immune Cell Therapy 78 | Azer-cel (azercabtagene zapreleucel) is an allogeneic chimeric antigen receptor T-cell (CAR-T) therapy comprising healthy donor T-cells engineered to express a chimeric antigen receptor (CAR) that targets CD19, which may lead to anti-tumor immune response against CD19-expressing tumor cells (J Clin Oncol 44 (16_suppl):7012). | |
| Cyclophosphamide | Cytoxan | CPM | Chemotherapy - Alkylating 18 | Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
| Fludarabine | Fludara | FAMP|Fludarabine phosphate | Fludara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary) | |
| Ibrutinib | Imbruvica | PCI-32765 | BTK inhibitor 39 EGFR Inhibitor (Pan) 63 HER2 Inhibitor 45 | Imbruvica (ibrutinib) is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK), which promotes apoptosis and inhibits B-cell mediated signaling pathways, and has additional activity against ERBB2 (HER2) and EGFR (PMID: 20615965, PMID: 21422473, PMID: 27678331). Imbruvica (Ibrutinib) is FDA approved for use in patients with CLL/SLL and CLL/SLL with del 17p, and Waldenstroem’s macroglobulinemia (FDA.gov). |
| Interleukin-12 | Ro 24-7472|NM-IL-12|Edodekin alfa | Interleukin-12 (NM-IL-12) is a recombinant version of Interleukin-12 (IL-12), which may decrease tumor angiogenesis (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|